Balázs Szigeti

Balázs Szigeti is a clinical researcher whose work focuses on rigorous methodology and reproducibility in psychedelic science and related neuropsychopharmacology. He has contributed to studies spanning psychedelic microdosing, clinical trials of psilocybin-assisted therapy, analyses of MDMA-assisted interventions, and empirical examinations of serotonergic effects following recreational MDMA use. Szigeti is known for emphasising blinded and preregistered designs, Bayesian analytic approaches and critical appraisal of effect size and expectancy confounds in the field.

His publication and trial involvement includes leading the self-blinding microdose trial that provided evidence for tolerance effects in psychedelic microdosing, contributing to an open-label dose-escalation psilocybin trial for bipolar II depression, assessing expectancy and suggestibility in comparisons of escitalopram versus psilocybin for depression, re-evaluating serotonergic alteration estimates following ecstasy use with neuroimaging implications, and participating in Bayesian analyses of MDMA-assisted psychotherapy outcomes for alcohol use disorder. Across these projects, he has emphasised methodological transparency, careful statistical inference and the clinical translation of psychedelic-assisted treatments.